
Episode 39: R-CHOP versus DA-EPOCH-R for Double-Hit Lymphoma
Alan Skarbnik, MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman, MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs dose-adjusted (DA)-EPOCH-R. The conversation gets testy when the trio describes double-hit lymphoma in terms of histology and phenotype,